APTO
NASDAQAptose Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Latest news
25 items- PRAptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML PopulationsTUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutationsSafety continues to be a notable hallmark of TUS-based therapies100% response rate (CR/CRh) at the two higher dose levels (80 and 120 mg TUS dose)CR/CRh observed in FLT3 wildtype subjects, representing ~70% of AML patientsCR/CRh observed in AML with TP53/complex karyotype, RAS, and MDS-related mutations SAN DIEGO and TORONTO, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat
- PRAptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY TrialAptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS, OTC:APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose's Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed with a 40 mg or 80 mg dose of tuspe
- SECAptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- PRAptose Announces Auditor Not Standing for Re-AppointmentSAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the "KPMG"), informed the Company that it will not stand for re-appointment for the Company's 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two fiscal quarters of 2025. The Company
- PRAptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceSAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025. Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with Aptose please contact your conference repre
- SECSEC Form PRER14A filed by Aptose Biosciences Inc.PRER14A - Aptose Biosciences Inc. (0000882361) (Filer)
- SECSEC Form 8-K filed by Aptose Biosciences Inc.8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- SECSEC Form PRE 14A filed by Aptose Biosciences Inc.PRE 14A - Aptose Biosciences Inc. (0000882361) (Filer)
- SECSEC Form 8-K filed by Aptose Biosciences Inc.8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- SECAptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- PRAptose Common Shares to Delist from Nasdaq as of April 2, 2025SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Nasdaq Hearings Panel (the "Panel") has determined to delist the common shares of the Company from The Nasdaq Stock Market ("Nasdaq" or the "Exchange"). Under the terms of the Panel's December 17, 2024, decision in this matter (the "Decision"), the Company was required to demonstrate compliance with the Exchange's equity requirement in Listing Rule 5550(b)(1
- SECSEC Form 10-K filed by Aptose Biosciences Inc.10-K - Aptose Biosciences Inc. (0000882361) (Filer)
- SECAptose Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- PRAptose Reports Year End 2024 Results and Corporate HighlightsTuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the year ended December 31, 2024, and provided a corporate update. "During 2024 and into 20
- SECAptose Biosciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- INSIDERNew insider Hanmi Pharmaceutical Co., Ltd. claimed ownership of 508,710 shares (SEC Form 3)3 - Aptose Biosciences Inc. (0000882361) (Issuer)
- SECAptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- PRAptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceSAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it is in compliance with Nasdaq's minimum bid price requirement. On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company's common shares has been $1.00 p
- SECAptose Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- SECAptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- PRAptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First CohortTUS+VEN+AZA triplet achieves complete responses (CRs) in difficult-to-treat TP53-mutated/CK AML and FLT3-wildtype AML patients, including a measurable residual disease (MRD) negative remission Dosing of initial 40 mg cohort complete; no prolonged myelosuppression or dose-limiting toxicitiesNo dose reductions to the standard-of-care components of the regimen (AZA/VEN) in first cohortCSRC endorses escalation to 80 mg dosing, enrollment is open SAN DIEGO and TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to tre
- SECAptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aptose Biosciences Inc. (0000882361) (Filer)
- PRAptose Announces Reverse Share SplitSAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that its board of directors (the "Board") has approved, subject to required regulatory and stock exchange approvals, a plan to consolidate all of its outstanding common shares (the "Common Shares") on the basis of 1 Common Share for every 30 Common Shares currently outstanding (the "Reverse Share Split"). The Company expects the Reverse Share Split to restore compliance with the minimum bid
- SECSEC Form S-1 filed by Aptose Biosciences Inc.S-1 - Aptose Biosciences Inc. (0000882361) (Filer)
- SECAptose Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Aptose Biosciences Inc. (0000882361) (Filer)
APTO FAQ
6 questionsWhat does Aptose Biosciences Inc. do?
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic...Where does APTO stock trade?
Aptose Biosciences Inc. (APTO) is listed on NASDAQ.What sector and industry is APTO in?
Aptose Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about APTO?
Aptose Biosciences Inc. has had 2 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $1200.00 price target on 2021-12-21. Recent price targets range from $1200.00 to $1400.00.What companies are similar to APTO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare APTO side-by-side with any of them on Quantisnow.How can I track APTO on Quantisnow?
Quantisnow aggregates Aptose Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APTO to receive live email and push alerts on every new disclosure.